Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Completed · Phase 3 · Has a placebo group

Conditions studied: Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions

In brief

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.

Key facts

Study ID: NCT01345019
Run by: Amgen
People needed: 1718
Starts: 2012-05-17
Expected to finish: 2019-03-29
Last updated by the study team: 2022-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Documented evidence of multiple myeloma (per local assessment):
Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or presence of a biopsy-proven plasmacytoma, and
Monoclonal protein present in the serum and/or urine
Radiographic (X-ray, or computer tomography [CT]) evidence of at least 1 lytic bone lesion (or at least 1 focal lesion per magnetic resonance imaging [MRI])
Plan to receive or is receiving primary frontline anti-myeloma therapies
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Age ≥ 18 years
Adequate organ function, as defined by the following criteria (per central or local laboratory values):
Serum aspartate aminotransferase (AST) ≤ 2.0 x upper limit of normal (ULN)
Serum alanine aminotransferase ≤ (ALT) 2.0 x ULN
Serum total bilirubin ≤ 2.0 x ULN
Creatinine clearance ≥ 30 mL/min
Serum calcium or albumin-adjusted serum calcium 2.0 mmol/L (8.0 mg/dL) and 2.9 mmol/L (11.5 mg/dL)
Written informed consent before any study-specific procedure is performed

You may not qualify if…

Nonsecretory multiple myeloma based upon standard M-component criteria (ie, measurable serum/urine M-component) unless the baseline serum free light chain level is elevated
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
Plasma cell leukemia
More than 30 days of previous treatment (before screening) with anti-myeloma therapy (does not include radiotherapy or a single short course of steroid [ie, less than or equal to the equivalent of dexamethasone 60 mg/day for 4 days]).
Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization)
Prior administration of denosumab
Use of oral bisphosphonates with a cumulative exposure of more than 1 year
More than 1 previous dose of IV bisphosphonate administration
Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw
Active dental or jaw condition which requires oral surgery, including tooth extraction
Non-healed dental/oral surgery, including tooth extraction
Planned invasive dental procedures
Evidence of any of the following conditions per subject self-report or medical chart review:
Any prior invasive malignancy within 5 years before randomization
Any non-invasive malignancy not treated with curative intent or with knownactive disease within 5 years before randomization
Major surgery or significant traumatic injury occurring within 4 weeks before randomization
Active infection with Hepatitis B virus or Hepatitis C virus
Known infection with human immunodeficiency virus (HIV)
Active infection requiring IV anti-infective therapy
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after end of treatment
Female subject of child bearing potential is not willing to use highly effective contraception during treatment and for 5 months after the end of treatment (see section 6.3)
Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
Subject is receiving or is less than 30 days since ending other experimental device or drug (no marketing authorization for any indication)
Subject will not be available for follow-up assessment
Any major medical or psychiatric disorder that in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results

Where it is running

Research Site — Fayetteville, Arkansas, United States
Research Site — Anaheim, California, United States
Research Site — Campbell, California, United States
Research Site — Encinitas, California, United States
Research Site — Fresno, California, United States
Research Site — Pleasant Hill, California, United States
Research Site — Santa Barbara, California, United States
Research Site — Santa Maria, California, United States
Research Site — Stamford, Connecticut, United States
Research Site — Washington D.C., District of Columbia, United States
Research Site — Washington D.C., District of Columbia, United States
Research Site — Boynton Beach, Florida, United States
Research Site — Boynton Beach, Florida, United States
Research Site — Jacksonville, Florida, United States
Research Site — Columbus, Georgia, United States
Research Site — Savannah, Georgia, United States
Research Site — Chicago, Illinois, United States
Research Site — Joliet, Illinois, United States
Research Site — Maywood, Illinois, United States
Research Site — Niles, Illinois, United States
Research Site — Skokie, Illinois, United States
Research Site — Skokie, Illinois, United States
Research Site — Anderson, Indiana, United States
Research Site — Fort Wayne, Indiana, United States
Research Site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.